Briefing Mind Cure Health Psychedelics

Mindcure Ends Fiscal Q1 2022 With $15.6 Million Cash & Cash Equivalents, $2.8 Million Net Loss

Mind Cure Health (CSE: MCUR) announced on Tuesday the financial results for the three months ended August 31, 2021. The firm ended the quarter with a $2.8 million net loss compared to fiscal Q1 2021’s net loss of $0.3 million. Among the company’s expenses for the quarter include $1.0 million in consulting fees and payroll, $0.2 …

Briefing KetamineOne Capital News Psychedelics

KetamineOne Announces Two Studies Focused On PTSD, Depression

KetamineOne Capital (NEO: MEDI) has officially begun its research programs. The firm this morning announced the inaugural launch of not one, but two research studies. The studies will be centered around that of PTSD and depression. The first study, classified as a single arm, open label study of persons with PTSD, will examine persons undergoing …

Briefing Psyched Wellness Psychedelics

Psyched Wellness Moves To Next Stage Of Pre-Clinical Trials With Mushroom Extract

Psyched Wellness (CSE: PSYC) continues to execute on its strategy as it pertains to the amanita muscaria mushroom. The company, through its contract research organization, KGK Science, has now begun the next pre-clinical trial study on its proprietary extract, referred to as AME-1. The next round of pre-clinical trials focuses on the beneficial or adverse …

Briefing Pharmather Psychedelics

PharmaTher To Raise $10.0 Million Via Institutional Investor Financing

PharmaTher Holdings (CSE: PHRM) this morning indicated that the company has secured a financing with institutional investors. The firm will be raising C$10.0 million via a financing conducted exclusively by H.C. Wainwright. The financing will see the company sell a total of 15.6 million units of the company price at $0.64 per each, with each …

Briefing Bright Minds Biosciences News Psychedelics

Bright Minds Biosciences Advances Lead Serotonergic Drug Candidate To Toxicology Studies, Targets Human Trials In 2022

Bright Minds Biosciences (CSE: DRUG) shared today scientific updates regarding its serotonergic drug pipeline. This includes the announcement of advancing the company’s proprietary agonist BMB-101 to the investigational new drug stage enabling safety and toxicology studies for its potential treatment of Dravet syndrome. The biotech firm is selecting BMB-101 as the lead drug candidate in …

Analyst Estimate Briefing Numinus Wellness Inc Psychedelics

Numinus Wellness: Eight Capital Initiates With $1.10 Price Target

Last week, Eight Capital launched coverage on a basket of psychedelic companies. This comes after they produced an industry primer during the summer months. The fourth company initiated on this note is Numinus Wellness Inc. (TSXV: NUMI), with a C$1.10 12-month price target and buy rating while referring to the firm as “a diversified operator.” …

Analyst Estimate Briefing Bright Minds Biosciences News Psychedelics

Bright Minds: Eight Capital Assigns $11.50 Price Target To Firm

Last week, Eight Capital launched coverage on a basket of psychedelic companies. This comes after they produced an industry primer during the summer months. The last company to be initiated on is Bright Minds Biosciences (CSE: DRUG), with an C$11.50 price target, or a 67% upside and a buy rating. Eight Capital headlines the note, …

Analyst Estimate Briefing Mind Medicine Psychedelics

Mindmed: Eight Capital Resumes Coverage With $6.50 Price Target

Earlier this week, Eight Capital launched coverage on a basket of psychedelic companies. This comes after they produced an industry primer during the summer months. They say that after a large influx of capital and “a growing body of clinical trial data on the use of psychedelics and related substances demonstrating a remarkable degree of …